M. Reck Et Al. , "Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.34, Illinois, United States Of America, 2016
Reck, M. Et Al. 2016. Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Reck, M., DeGreen, H. P., Rose, A. L., Pavlakis, N., Derjcke, S. M., Radic, J., ... Jeppesen, N.(2016). Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial. . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Reck, Martin Et Al. "Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2016
Reck, Martin Et Al. "Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2016
Reck, M. Et Al. (2016) . "Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Martin Reck Et Al. }, title={Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2016}}